SNS-INSIDER-300X300.jpg
Growth Hormone Deficiency Market Size to Hit USD 8.5 Billion by 2032 | SNS Insider
10. September 2024 09:00 ET | SNS Insider pvt ltd
Pune, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Growth Hormone Deficiency Market Size & Share Analysis: “According to SNS Insider, The Growth hormone deficiency Market was valued at USD 5.4 billion...
Logo 1.png
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
13. Juni 2024 09:10 ET | Aeterna Zentaris Inc
Company expects to report top-line data and complete study results in Q3 2024 TORONTO, ONTARIO, June 13, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or...
Logo 1.png
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
12. März 2024 14:10 ET | Aeterna Zentaris Inc
TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce...
Logo 1.png
Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities
26. Januar 2022 08:05 ET | Aeterna Zentaris Inc
– Company advancing diversified portfolio focused on areas of significant unmet medical need– Supported by solid financial position with cash to fund operations beyond 2023 TORONTO,...
AMR Logo.png
Global Human Growth Hormone Market to reach $9.21 billion by 2030: Allied Market Research
11. Oktober 2021 04:12 ET | Allied Market Research
Portland, OR, Oct. 11, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Human Growth Hormone Market generated $3.86 billion in 2020, and is projected...
Logo 1.png
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
13. Mai 2021 08:05 ET | Aeterna Zentaris Inc
– Safety and efficacy study for macimorelin initiated as agreed with U.S. FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP") – Patient enrollment on...
gmi logo.jpg
Growth Hormone Market revenue to cross USD 5.3 Bn by 2027: Global Market Insights Inc.
29. April 2021 07:00 ET | Global Market Insights, Inc
Selbyville, Delaware, April 29, 2021 (GLOBE NEWSWIRE) -- According to latest report “Growth Hormone Market by Product (Powder, Solvent), Application (Growth Hormone Deficiency, Idiopathic Short...
Logo 1.png
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
22. März 2021 16:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology
08. September 2020 08:05 ET | Aeterna Zentaris Inc
- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults - - Data from this study support the choice of 1.0 mg/kg dose of...
Ascendis_FINAL_LOGO_7.23.15.png
Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency
04. März 2019 06:30 ET | Ascendis Pharma A/S
- TransCon hGH demonstrated comparable safety and tolerability to a daily hGH - - Potential once-weekly treatment option to overcome long-standing challenges with administration of daily hGH - -...